Australia's Medical Cannabis Exports Surge as Imports Balloon Too
Photo by Andy Li via Unsplash.
Walk into the numbers on Australia's medical cannabis trade and they don't add up at first glance. In 2024 the country imported more than 75 tonnes of medical cannabis, cementing its position as the region's biggest buyer of foreign product. In that same year, domestic cultivation hit a record 42,400 kg, and Australian growers pushed exports to New Zealand up 178%, making it the country's largest single export market almost overnight. So which is it -- is Australia a cannabis-hungry importer leaning on Canadian supply chains, or a rising exporter carving out shelf space in Europe and the Pacific?
The honest answer is both, and that's not a contradiction so much as a snapshot of an industry sorting itself into tiers. Some Australian cultivators are producing bulk flower and extract that can't find a profitable home in an increasingly crowded domestic market, so it heads offshore. Meanwhile local prescribers and pharmacies are pulling in enormous volumes of imported product -- much of it from Canada -- because domestic supply, even at record highs, still can't match what a fast-growing telehealth-driven prescription base demands. Two data points due later this year and next -- a telehealth consultation outcome and a delayed 2025 export dataset -- will start to clarify which side of this ledger is going to define the next phase of the industry.
A Supply Glut Meets a Growing Export Business
Australia's domestic cannabis production grew markedly from 16,500 kg in 2021 to 42,400 kg in 2024, yet imports of 75,000 kg in 2024 still far outpace local output, highlighting continued reliance on foreign supply.
The scale of Australia's domestic cultivation growth is genuinely striking. Office of Drug Control figures put 2024 production at 42,400 kg, a 60% jump from 2023. The consultancy HCPA, which tracks the sector closely, frames the longer arc even more starkly: domestic output has gone from roughly 16-17 tonnes in 2021 to more than 40 tonnes now, roughly two-and-a-half times in three years. That's not incremental growth from a handful of new licenses -- it reflects a cohort of cultivators that scaled greenhouse and indoor capacity aggressively, betting that Australia's prescription-driven demand curve would keep climbing.
It has kept climbing, just faster than local growers could keep pace with. Imports topped 75 tonnes in 2024 and have made up more than 60% of total supply in recent years, even as domestic production hit its own records. Put another way: Australian cultivation nearly tripled in three years and still lost relative ground to imports, which grew almost tenfold over the same period. That's the scale mismatch that explains the seemingly contradictory headlines -- both sides of the equation are growing, but demand is simply outrunning local capacity to serve it, at least for the products the market wants right now.
Canada remains the dominant supplier into this gap, leaning on its established GMP-certified export infrastructure built over nearly a decade of legal cannabis production. The scale of the flow is genuinely notable in a global context: Australia now imports more medical cannabis than Germany, long considered Europe's flagship prescription market. That's partly a function of Australia's comparatively permissive telehealth prescribing environment generating patient volumes that outstrip what local growers, even at record output, have been licensed and equipped to supply domestically.
New Zealand Becomes Australia's Top Export Market
Photo by World Sikh Organization of Canada via Pexels.
New Zealand's emergence as Australia's top export destination in 2024 is one of the clearer signals of where the export side of this industry is actually headed in the near term. Shipments to New Zealand rose 178% that year, and the market ended up absorbing close to half of all Australian medical cannabis exports -- a remarkable concentration in a single destination for an industry that has spent years talking up Europe as the ultimate prize.
The shift makes sense once you look past the headline percentage. New Zealand runs its own prescription cannabis scheme with regulatory recognition pathways that align reasonably well with Australia's TGA framework, cutting down the friction and lead time involved in getting product approved for a new market. Geographic proximity matters too -- shorter shipping times matter for a product with shelf-life and chain-of-custody requirements, and the two countries' regulators have built enough mutual familiarity that Australian exporters can move product without the multi-year approval slog that markets like Germany or the UK can involve.
Historically, Europe held the export crown. ODC data shows Germany taking 935 kg of Australian medical cannabis in 2022 and the UK importing 407 kg the same year -- respectable volumes that fed the narrative of Australia as an emerging supplier to the world's most mature prescription cannabis markets. But that dataset is now several years stale, and it's worth being upfront about the gap: the ODC's own publication schedule doesn't have updated 2025 export figures landing until the third quarter of 2026. That leaves a real blind spot on how much the export mix has shifted since, and whether New Zealand's 2024 surge was a one-off reflecting timing of shipments, or the start of a durable reordering of Australia's export priorities toward its closest neighbor rather than its most talked-about one.
Little Green Pharma and Cannatrek Bet Big on Europe
Photo by Elements Interactive via Pexels.
Little Green Pharma has been unusually candid about why it's chasing European revenue. Reporting from Kalkine Media in July 2026 laid out the company's position plainly: domestic margins have been squeezed as more growers compete for a home market that, despite growing patient numbers, has seen wholesale prices fall in a familiar oversupply pattern. When your own backyard is saturated and prices are compressed, geographic diversification stops being a growth strategy and starts being a margin-protection strategy.
Europe, and Germany specifically, has offered exactly the kind of demand that domestic cultivation there can't satisfy. Germany's cannabis access reforms have widened the pool of patients able to obtain prescription cannabis, and local European cultivation capacity -- constrained by licensing, land, and years of underinvestment relative to demand -- simply hasn't scaled fast enough to fill the gap. That mismatch is Australia's opening, and it's a mirror image of the dynamic driving Australia's own import numbers: wherever cultivation lags prescription growth, someone else's surplus product fills the space.
The clearest signal of how seriously Australian firms are taking this opportunity came in January 2026, when Little Green Pharma announced a merger with Cannatrek. The combined entity carries pro forma revenue of USD 75.4 million, a scale that puts it in a different competitive category than either company operated in alone. More significant than the revenue figure is the manufacturing footprint: the merged group holds GMP-certified manufacturing in both Australia and Denmark, which means it can produce finished product inside the EU regulatory perimeter rather than relying solely on cross-border export approvals for every shipment. That's a structural advantage -- it turns a trade relationship into something closer to a genuine EU manufacturing presence, and it's the kind of move that tends to matter more over a five-year horizon than any single year's export tonnage.
ECS Botanics and the Push Into the UK and Germany
Photo by Terrance Barksdale via Pexels.
ECS Botanics has taken a narrower but complementary route into the same European opportunity, securing export approvals to move Australian-grown medicinal cannabis directly into both the UK and Germany. Rather than building or acquiring EU-based manufacturing the way Little Green Pharma and Cannatrek have done through their merger, ECS Botanics' model leans on getting Australian-grown product through the pharmaceutical import standards these markets require -- a process that hinges on GMP-aligned manufacturing integration back home rather than a European production footprint.
That distinction matters for understanding where Australia's competitive edge actually sits. Getting product accepted into Germany or the UK isn't primarily a cultivation problem -- Australian growers can produce flower at competitive cost and quality. It's a compliance and manufacturing-standards problem, since EU pharmaceutical import requirements demand documentation, batch consistency, and facility certification that go well beyond what's needed to sell into Australia's own domestic prescription market. Companies that get GMP alignment right earn access to the two biggest entry points in European medical cannabis: Germany's reformed, expanding prescription system and the UK's private prescription pathway, which has quietly become one of Europe's largest channels for patient access outside a fully public system.
What's notable is how quickly the playbook is spreading beyond the two or three companies that pioneered it. Smaller and mid-tier Australian cultivators are increasingly pursuing the same export-approval route ECS Botanics and Little Green Pharma have proven out, treating GMP certification less as a competitive moat to guard and more as table stakes for participating in export markets at all. As more Australian producers clear that bar, the binding constraint on export growth shifts away from any single company's approvals and toward the aggregate capacity of Australia's manufacturing base to meet EU-grade standards at volume.
The Rules Behind the Trade
Photo by AymaneJed via Pixabay.
None of this trade happens outside a fairly dense regulatory scaffolding. Exports and imports both run through the Office of Drug Control under the Narcotic Drugs Act 1967 and the Narcotic Drugs Regulation 2016, the federal framework that licenses cultivation, production, and manufacture of medicinal cannabis in Australia. Layered on top of that are the Customs (Prohibited Exports) Regulations 1958, which govern what can physically leave the country, and ongoing Therapeutic Goods Administration oversight of the products themselves, alongside separate state and territory regulatory bodies that touch different parts of the supply chain. It's a multi-agency system, and every additional layer adds time to getting new export or import approvals through.
The regulatory story to watch right now sits closer to home than any export market. A public consultation on tightening Australia's telehealth prescription system closed in late November 2025, and the outcome is still pending. Australia's telehealth pathway has been comparatively loose by international standards, which is a large part of why domestic patient numbers -- and therefore import demand -- have grown as fast as they have. If regulators move to tighten prescribing rules, the effect on the supply glut driving exports could cut either way: fewer domestic prescriptions could free up cultivated product that currently serves the home market, pushing more volume toward export; or it could cool the demand growth that's made Australian cultivation licenses attractive investments in the first place, denting the incentive to keep expanding domestic capacity at all.
Sizing the market itself is an exercise in reading a range rather than a single number -- estimates vary meaningfully by source, but most place Australia's medical cannabis market at somewhere between roughly US$0.6 billion and US$1 billion in 2025, with projections reaching anywhere from US$1.6 billion to US$4 billion by the early-to-mid 2030s. That's a wide band, and it says as much about how unsettled forecasting methodologies are in this sector as it does about the underlying growth trend, which most analysts agree is real even if its precise magnitude is still up for debate.
Framed as a paradox, the simultaneous import surge and export boom makes for a catchy headline. Framed as market segmentation, it makes a lot more sense. Australia is still figuring out which parts of the medical cannabis value chain it can actually compete in globally -- raw flower, GMP-certified extract, or finished pharmaceutical product -- versus which parts it's better off simply buying in from Canada while local demand outpaces local supply. Right now the answer looks tiered: Australia imports bulk product to feed a telehealth-driven domestic market growing faster than its own cultivation licenses can serve, while its more capable manufacturers export higher-margin, compliance-heavy product into markets like New Zealand, Germany, and the UK where local supply is the constrained resource instead.
Two data releases will do more to clarify this than any single company's earnings call. The telehealth consultation that closed in November 2025 will determine whether Australia's prescription growth engine keeps running at its current pace or gets throttled back, which flows directly into how much surplus cultivation is looking for an export home. And the ODC's 2025 export figures, not due until Q3 2026, will finally show whether New Zealand's 178% jump was the start of a durable reordering of Australia's export priorities or a one-year anomaly inflated by shipment timing. Until both land, anyone calling this export growth durable is working from an educated guess.
What does look durable is the shift in where Australia's real competitive advantage sits. It was never going to be cheap cultivation alone -- plenty of countries can grow cannabis cheaply. It's GMP-certified manufacturing and export licensing infrastructure, the unglamorous compliance machinery that actually gets product across borders and onto pharmacy shelves in regulated markets. That's exactly why the Little Green Pharma-Cannatrek merger, with its dual Australia-Denmark manufacturing footprint, deserves more attention than any single year's export tonnage figure. Tonnage tells you what happened last year. Manufacturing infrastructure tells you what's still possible five years from now.